Patents over minor incremental developments (often termed as ‘evergreening’ patents ) may be used to exclude generic competition and thereby block access to affordable drugs. They may constitute an important obstacle for the realization of the right to health recognized in the International Covenant on Economic, Social and Cultural Rights and, growingly, in the national constitutions of many countries.